Quince Therapeutics Announces 1-for-10 Reverse Stock Split Effective April 10, 2026

South San Francisco, CA – April 9, 2026 – Quince Therapeutics, Inc. (Nasdaq: QNCX) has announced a significant corporate action that will impact all shareholders: a 1-for-10 reverse stock split of its common stock. The split was approved by shareholders at the company’s 2025 Annual Meeting on June 4, 2025, and was formally authorized by the company’s Board of Directors. The Certificate of Amendment to the Amended and Restated Certificate of Incorporation was filed today with the Secretary of State of Delaware, and the split will become effective at 11:59 p.m. Eastern Time on April 10, 2026. The company’s shares will begin trading on a split-adjusted basis on the Nasdaq Global Select Market at market open on April 13, 2026.

Key Details of the Reverse Stock Split

• Reverse Split Ratio: Every ten (10) shares of issued and outstanding common stock will be automatically combined and converted into one (1) share of common stock.
• No Impact on Percentage Ownership: The reverse stock split will affect all shareholders uniformly and will not alter their percentage ownership in the company, except for the treatment of fractional shares.
• Fractional Shares: Shareholders who would otherwise be entitled to a fractional share will receive cash in lieu of such fractional shares. The value will be based on the closing sales price of Quince’s common stock on the Nasdaq Global Select Market on the date of the filing of the Certificate of Amendment.
• Options and Warrants: All outstanding stock options and warrants will be proportionally adjusted to reflect the reverse split.
• New CUSIP Number: The company’s common shares will trade under a new CUSIP number, 22053A206, starting April 13, 2026, but will continue to use the trading symbol “QNCX”.
• Post-Split Shares Outstanding: Immediately after the split, approximately 16,300,795 shares of common stock will be issued and outstanding.
• Transfer Agent: Equiniti Trust Company, LLC will serve as the exchange agent. Shareholders holding shares through a bank, broker, or other nominee will have their positions automatically adjusted and do not need to take further action, subject to their broker’s specific processes.

What Shareholders Should Know

• Potential Share Price Impact: The reverse stock split is expected to increase the per-share trading price of Quince Therapeutics’ common stock. This action is often taken to help companies comply with exchange listing requirements or to make the stock more attractive to institutional investors who may shy away from low-priced stocks.
• Price Sensitivity: Reverse stock splits can be perceived both positively and negatively by the market. While the absolute value of a shareholder’s investment should not change (excluding rounding for fractional shares), the market may interpret the split as a signal regarding the company’s outlook, which could impact share price volatility in the short term.
• Administrative Implications: Shareholders do not need to physically exchange their stock certificates if they hold shares electronically. Those holding physical certificates will be contacted by the exchange agent with instructions if any action is required.
• Corporate Governance: This action was approved by shareholders and the board, indicating strong corporate governance and alignment with shareholder interests.
• Regulatory Compliance: The split and the amendment to the Certificate of Incorporation were conducted in accordance with Delaware law and SEC requirements.

Important Documents

• The Certificate of Amendment is available as Exhibit 3.1 to the company’s 8-K filing and provides the full legal text of the changes to the Certificate of Incorporation.

Conclusion

This reverse stock split is a material corporate event for Quince Therapeutics and its shareholders. It is designed to strengthen the company’s capital structure and potentially support its continued listing on the Nasdaq Global Select Market. Investors should monitor trading in the days following April 13, 2026, for market reactions. As with all corporate actions, shareholders are encouraged to consult with their financial advisors regarding the implications for their individual holdings.

Disclaimer: This article is intended for informational purposes only and does not constitute investment advice. Investors are advised to review the company’s official filings with the U.S. Securities and Exchange Commission and consult with their financial advisors before making any investment decisions. The information provided is based on the company’s SEC Form 8-K filing dated April 9, 2026.

View Quince Therapeutics, Inc. Historical chart here